Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pulmonary infection
Show results for
Products

Companies

News
Articles
Books
Downloads

Refine by
Date

  • Older

Pulmonary Infection Articles & Analysis

7 news found

Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...

ByBeyond Air Inc


Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference

Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


FRI - Understanding The Link Between Pulmonary Vasculature Abnormalities and DCLO in Covid-19

FRI - Understanding The Link Between Pulmonary Vasculature Abnormalities and DCLO in Covid-19

Abnormalities in pulmonary function tests infection have been described. The determinants of these abnormalities are still unclear. 38 subjects were included in the study. CT images were evaluated by Functional Respiratory Imaging with automated tissue segmentation algorithms of the lungs and pulmonary vasculature. The diffusion capacity of ...

ByFluidda


Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline

Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline

Roden — July 7, 2021 — Mycobacterium abscessus is a nontuberculous mycobacterium (NTM) that primarily causes severe pulmonary infections. The pathogen is also known as the ‘antibiotic nightmare’, due to its resistance to nearly all antibiotics. ...

ByPureims B.V.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT